Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-β Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease
暂无分享,去创建一个
Rajiv Chopra | Kullervo Hynynen | JoAnne McLaurin | Isabelle Aubert | Yuexi Huang | K. Hynynen | Rajiv Chopra | J. McLaurin | Yuexi Huang | Kelly A. Markham | Carlos A. Ayala-Grosso | Jessica F. Jordão | I. Aubert | J. Jordão | C. Ayala-Grosso | Kelly Markham
[1] Dave Morgan,et al. Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation , 2003, The Journal of Neuroscience.
[2] D. Wilcock,et al. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage , 2004, Journal of Neuroinflammation.
[3] Kullervo Hynynen,et al. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. , 2008, Ultrasound in medicine & biology.
[4] S. M. Robinson,et al. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. , 2002, Peptides.
[5] Natalia Vykhodtseva,et al. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. , 2006, Journal of neurosurgery.
[6] Rajiv Chopra,et al. An MRI-compatible system for focused ultrasound experiments in small animal models. , 2009, Medical physics.
[7] B. Hyman,et al. Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.
[8] S. M. Robinson,et al. Passage of amyloid β protein antibody across the blood–brain barrier in a mouse model of Alzheimer’s disease , 2002, Peptides.
[9] C. Colton,et al. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. , 2008, Journal of Alzheimer's disease : JAD.
[10] Alisa Opar. Mixed results for disease-modification strategies for Alzheimer's disease , 2008, Nature Reviews Drug Discovery.
[11] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[12] D. Thakker,et al. Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice , 2009, Proceedings of the National Academy of Sciences.
[13] M. Balass,et al. N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies , 1998, Journal of Neuroimmunology.
[14] J. McLaurin,et al. Immunotherapy as treatment for Alzheimer’s disease , 2007, Expert review of neurotherapeutics.
[15] D. Wilcock,et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[16] D. Holtzman,et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] D. Westaway,et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis , 2002, Nature Medicine.
[18] Xin Wu,et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.
[19] K. Hynynen,et al. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. , 2006, Biochemical and biophysical research communications.
[20] S. Turner,et al. Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695* , 2001, The Journal of Biological Chemistry.
[21] K. Hynynen,et al. Ultrasound Enhanced Delivery of Molecular Imaging and Therapeutic Agents in Alzheimer's Disease Mouse Models , 2008, PloS one.
[22] H. Weiner,et al. Immunology and immunotherapy of Alzheimer's disease , 2006, Nature Reviews Immunology.
[23] K. Hynynen,et al. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. , 2004, Ultrasound in medicine & biology.
[24] J. McLaurin,et al. Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. , 2009, Vaccine.
[25] Manabu Kinoshita,et al. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[26] David J. Cummins,et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[27] D. Westaway,et al. Impaired conditioned taste aversion learning in APP transgenic mice , 2004, Neurobiology of Aging.
[28] K. Hynynen,et al. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.
[29] Reinhard Schliebs,et al. Longitudinal assessment of Alzheimer's β‐amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging , 2006, Journal of magnetic resonance imaging : JMRI.
[30] Ralph A. Nixon,et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.
[31] P. S. St George-Hyslop,et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. , 2002, Nature medicine.
[32] P. S. St George-Hyslop,et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. , 2000, Nature.
[33] D. Westaway,et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.